Syntax Bio to Present New Cellgorithm™ Research at ISSCR iPSC 20th Anniversary Symposium in Kyoto
Syntax Bio to Present New Cellgorithm™ Research at ISSCR iPSC 20th Anniversary Symposium in Kyoto
Syntax Bio will present new research on its Cellgorithm™ cell-programming platform at the International Society for Stem Cell Research (ISSCR) iPSC 20th Anniversary Symposium, held Oct. 20-22 at the Kyoto International Conference Center in Kyoto, Japan.
The research showed that Cellgorithm differentiated human induced pluripotent stem cells (iPSC) toward pancreatic beta cell states in four days. The study also identified genetic 'gridlocks' that stall cells at intermediate stages of development.
The findings could support more precise control over stem cell programming and faster, more reliable and scalable production of specialized cells for therapeutic use.
Syntax Bio co-founder and chief scientific officer Ryan Clarke, PhD, and chief executive officer John Craighead, PhD, will be available in Kyoto to discuss the findings and their implications for cell therapy development. To schedule an interview, contact Matt Burns.
Oral Presentation
Title: Cellgorithms: Programming Human iPSC Differentiation With Modular, Time-Resolved CRISPRa Cascades
Presenter: Ryan Clarke, PhD, co-founder and chief scientific officer, Syntax Bio
Date and time: Oct. 21, 2026, 10:10-10:30 a.m. Japan Standard Time (UTC+9)
Location: Event Hall
Poster Presentation
Title: Cellgorithms: Programming Human iPSC Differentiation with Modular, Time-Resolved CRISPRa Cascades
Presenter: Ryan Clarke, PhD, co-founder and chief scientific officer, Syntax Bio
Poster number: 288
Date and time: Oct. 21, 2026, 6:00-6:45 p.m. Japan Standard Time (UTC+9)
Location: New Hall
About Syntax Bio
Syntax Bio is a synthetic biology company programming the next generation of regenerative medicines. Its proprietary Cellgorithm™ platform uses a CRISPR-based system to program and accelerate stem cell differentiation, transforming how cell therapies are discovered, developed and manufactured. By replacing slow, labor-intensive differentiation processes with a rapid, programmable approach that mimics human development, Syntax Bio can generate specialized cells in days or weeks rather than months, more reliably and at scale, unlocking new possibilities across the biotechnology industry. Learn more at syntax-bio.com.
Media Contact:
Matt Burns
Acumen Strategies
matt@acumen-strategies.com
518-423-5907
View source version on businesswire.com: https://www.businesswire.com/news/home/20261013127005/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
These Overvalued Stocks Have Plenty of Room to Fall
The 10 Best Companies to Invest in Now
Your Year-End Financial Checklist: 5 Things to Tackle Before 2027
4 Growth Stocks to Buy While They’re Still Undervalued
United States